Page 17 - Sun Pharma

Sun Pharma gets 6 observations by US FDA after inspection at Halol facility

Shares of Sun Pharmaceutical Industries on Friday closed at Rs 664.20 per scrip on BSE, down 1.84 per cent from its close

Sun Pharma erases losses post clarification on USFDA observations

The stock hit an intra-day high of Rs 670, recovering 4.7% from its early morning low of Rs 640 on the NSE.

Sun Pharma falls 5% on reports of USFDA issues observations

In past three months, Sun Pharma had outperformed the market by surging 38% as compared to a 9% rise in the benchmark index till Thursday.

Sun Pharma, Glenmark Pharma, Hikal hit 52-week highs; Aurobindo surges 8%

Granules India, Hikal, Pfizer, Lincoln Pharmaceuticals, Astrazeneca Pharma India and Aarti Drugs were up between 4% and 7%.

Improved US prospects, domestic outlook to drive Sun Pharma's earnings

The key near-term trigger is the company's specialty pipeline

Pharma shares extend rally; Dr Reddy's, Sun Pharma hit 52-week high

In past 14 trading days, Nifty Pharma index outperformed the market by surging 15% as compared to 2.3% rise in Nifty 50 index.

Nifty Pharma index set to post sharpest monthly rally in 9 years

Nifty Pharma index hit a fresh 52-week high of 10,390 in intra-day on Friday, rallying 13% thus far in the month of August, its sharpest monthly gain since September 2009.

US drug regulator inspects Sun Pharmaceutical's Halol plant in Gujarat

Sun Pharma had recalled around 5,000 units of 10 ml vials of testosterone cypionate injections from the US

Nifty Pharma index hits over six-month high; Sun Pharma at 14-month high

Thus far in current week, the Nifty Pharma index outperformed the market by surging 7% against a marginal 0.31% rise in the Nifty 50 index.

Sun Pharma hits 52-week high on USFDA approval, good Q1 results

Sun Pharm hit a 52-week high of Rs 618, up 3%, extending its Tuesday's 7% rally on the BSE.

Earnings upgrades ahead for Sun Pharmaceutical, stock gains nearly 7%

US growth at 8%, despite declining Taro sales, giving confidence that the firm is on a recovery path in America

Sun Pharma posts Rs 9.8 bn Q1 profit, beats estimates as US sales climb

Sales from its US formulations business, which constitutes over a third of total sales, grew 8 per cent from the previous corresponding quarter

Sun Pharma rallies 7% as Q1 profit beats Street estimates

The stock rallied 7% to Rs 600 on the BSE after the company reported a better-than-expected consolidated net profit at Rs 9.83 billion in June quarter.

Pharma shares in focus; Nifty Pharma index hits 6-month high

Divi's Lab, Aurobindo Pharma, Lupin, Dr Reddy's Lab, Sun Pharma, Glenmark Pharma and Cipla from the Nifty pharma index were up in the range of 1% to 3% on the NSE.

Sun Pharma gets USFDA approval to produce cancer injection from Halol site

Halol's non-compliance has held up fresh product approvals from the site for nearly four years, and is partly responsible for the muted growth in the US for Sun.

Markets trade flat, Sun Pharma advances

Markets trade flat, Sun Pharma advances

Sun Pharma nears 52-week high as stock surges 32% in five weeks

The stock was trading 2% higher at Rs 587 on the BSE in otherwise subdued market, trading nears to 52-week high of Rs 609 touched on February 12, 2018.

Sun Pharma sharpens R&D for efficiencies with digital applications

The drug maker has guided for an increase in R&D expenses in FY 19 as it builds a pipeline of specialty products

Pharma shares extend gain in subdued market; Aurobindo, Divi's Labs up 4%

At 03:16 pm; the Nifty Pharma index, the sole gainer among sectoral indices, was up 2%, as compared to 0.49% decline in Nifty 50 index.

Sun Pharma extends rally on EIR from USFDA for Halol facility

The stock was up 4% to Rs 561 on BSE in early morning trade, extending its past five days 14% rally, after the company announced the resolution of regulatory compliance issues at Halol plant.